Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AC Immune and J&J Advance Tau-Targeting Alzheimer’s Vaccine

Encouraging Early Efficacy Signs

Executive Summary

AC Immune has seen two big disappointments in its Alzheimer’s pipeline this year, but its partner Johnson & Johnson has put its faith in a novel vaccine-like approach to targeting the disease.

You may also be interested in...



Eisai/Biogen’s Lecanemab Effective Across Endpoints, But Will Safety Limit Use?

Alzheimer’s patients treated with the amyloid protofibril-clearing antibody had slower disease progression compared to placebo, with differences increasing over time. Safety concerns, however, are growing. 

Failure Of Roche’s Nine-Year Alzheimer’s Prevention Study Disappointing, But No Surprise

The ambitious prevention study in people with a nearly 100% chance of developing Alzheimer’s disease has failed, and attention will now switch to trial readouts for the next generation of beta-amyloid targeting candidates.

After ‘Puzzling’ Results For Antibody Drug, AC Immune’s Alzheimer’s Vaccine Shows Early Promise

Another hard-to-explain result in Alzheimer’s, with AC Immune claiming the first ever validation of anti-tau therapy, but others are more circumspect.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC147462

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel